Report Highlights
The global market for companion diagnostics is estimated to increase from $7.6 billion in 2023 to reach $15.4 billion by 2028, at a compound annual growth rate (CAGR) of 15.2% from 2023 through 2028.
Report Includes
- 54 data tables and 59 additional tables
- Overview and an analysis of the global markets for companion diagnostics (CDx).
- Analyses of the global market trends, with historical market revenue data (sales figures) from 2021 to 2022, estimates for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028.
- A look at the current and future market potential of companion diagnostics along with the market dynamics, competitive landscape and regulatory scenario.
- Estimate of the market size and revenue forecast for the global CDx market, and corresponding market share analysis based on product and services, test type, technology, application, end user and region.
- Discussion of the market opportunities for CDx products by identification of high-growth applications in different therapeutic areas, with a focus on the largest and fastest-expanding markets for diseases.
- Analysis of recent market developments and clinical trials, as well as the leading companies engaged in R&D and product developments in CDx reagents.
- Discussion of the importance of ESG in the CDx industry, including consumer attitudes, the impact of ESG on company performance, ESG score analysis, and ESG practices followed by leading companies.
- Review of key patent grants and patent applications related to CDx.
- Identification of the major vendors along with an analysis of the competitive intelligence, including companies’ market shares, recent M&A activity, and venture funding outlook.
- Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., and QIAGEN
Report Scope
The current report provides detailed coverage of the companion diagnostics market. This report highlights the current and future market potential of companion diagnostics, and it includes a detailed analysis of the drivers, opportunities, restraints, and challenges in the market. The report details the companion diagnostics market share based on product and service, type of test, technology, and application. The market’s products and services is segmented into instruments, consumables, and services. It is categorized based on the type of test into commercial CDx and lab-developed tests (LDT)-CDx. Based on technology, the market is segmented into polymerase chain reaction, immunohistochemistry, next-generation sequencing, in situ hybridization, genotyping, immunoassays, exosomes, others, and services market. Based on application, the CDx market is categorized into cancer, neurologic disorders, cardiovascular disease, infectious disease, and others. Based on end users, the companion diagnostics market is segmented into clinical laboratories, pharmaceutical companies, contract research organizations (CROs), and other end users. The report also includes company profiles of the major players in the companion diagnostics market, with details about each company's business segments, financials, product portfolios, and recent developments.
By geographical region, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The North America region includes the U.S. and Canada; Europe includes Germany, the U.K., Italy, France, and the Rest of Europe; Asia-Pacific includes China, India, Japan, and the Rest of Asia-Pacific. For market estimates, data has been provided for 2020 and 2021 as the historic years, 2022 as the base year, and 2028 as the forecast year.
Report Synopsis
| Report Metrics | Details | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2022 | ||||||||||
| Forecast period considered | 2023-2028 | ||||||||||
| Base year market size | $6.6 billion | ||||||||||
| Market size forecast | $15.4 billion | ||||||||||
| Growth rate | CAGR of 15.2% for the forecast period of 2023-2028 | ||||||||||
| Units considered | $ Millions | ||||||||||
| Segments covered | Product and Service, Type of Test, Technology, Application, End User | ||||||||||
| Regions covered | North America, Europe, Asia-Pacific, Rest of the World (RoW) | ||||||||||
| Countries covered | U.S., Canada, Germany, France, U.K., Italy, Rest of Europe, China, India, Japan, Rest of Asia-Pacific | ||||||||||
| Key Market Drivers |
|
||||||||||
| Companies studied |
|
Frequently Asked Questions (FAQs)
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Report Highlights
The global market for companion diagnostics (CDx) is estimated to increase from $6.4 billion in 2022 to reach $13.0 billion by 2027, at a compound annual growth rate (CAGR) of 15.3% from 2022 through 2027.
Report Includes
- 43 data tables and 60 additional tables
- Detailed overview and an up-to-date analysis of the global market for companion diagnostics (CDx)
- Analyses of the global market trends, with historic market revenue data for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Estimation of the actual market size and revenue forecast for the global CDx market in USD million values, and corresponding market share analysis by product and service, technology, application, type of test, and region
- Identification of the viable technology drivers and barriers through a holistic review of various platform technologies and their potential applications in the development of new CDx products
- Discussion of feasible market opportunities for companion diagnostics products via identification of high-growth applications in different therapeutic areas, with a focus on the biggest and fastest-expanding markets for diseases
- Updated information on recent market developments and clinical trials, as well as the leading companies engaged in research and development (R&D) and products in the companion diagnostics reagent pipeline with SWOT analyses
- Review of the patents and patent applications on companion diagnostics and deep dive of recent patent publications related to CDx products and technologies
- Insight into the recent industry structure of companion diagnostics, competitive aspects of each product segments, increasing investment on R&D activities, market growth strategies, and company revenue share analysis
- Descriptive company profiles of the leading global players, including Abbott Laboratories, Bio-Rad Laboratories Inc., Illumina Inc., Foundation Medicine Inc., Myriad Genetics Inc., F. Hoffmann-La Roche Ltd., Qiagen N.V., and Thermo Fisher Scientific Inc.
Report Highlights
The global market for companion diagnostics (CDx) is estimated to grow from $5.4 billion in 2021 to reach $10.7 billion by 2026, at a compound annual growth rate (CAGR) of 14.6% during the forecast period of 2021-2026.
Report Includes
- 53 data tables and 44 additional tables
- An overview of the global market for companion diagnostic (CDx) technologies
- Analyses of the global market trends, with data from 2019-2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
- Evaluation of current market size, market forecast, and technological advancements within the industry and discussion on technical issues related to biomarker stability and storage
- Market share analysis of global CDx market by solution and type of test, technology, application, and geographic region
- Information on biomarkers, their role in precision medicine and discussion on potential use of biomarkers in the development of companion diagnostics (CDx)
- Insights into CDx approvals and FDA guidelines for new drugs and description of predictive genomic biomarkers for immunotherapy including microsatellite instability (MSI) and tumor mutational burden (TMB)
- Coverage of new CDx product developments, clinical trials, patents issued, mergers and acquisitions, partnerships, collaborations and other effective market development strategies
- Comprehensive company profiles of major industry players, including Adaptive Biotechnologies, Exact Sciences Corp., Exosome Diagnostics Inc., Foundation Medicine Inc., Myriad Genetic Laboratories Inc., Roche Molecular Systems Inc., Prometheus Biosciences, Qiagen and Thermo Fisher Scientific Inc.
Report Highlights
The global market for companion diagnostics reached nearly $3.2 billion in 2015. This market is expected to increase from $4.3 billion in 2016 to nearly $17.6 billion in 2021 at a compound annual growth rate (CAGR) of 32.3% for 2016-2021.
Report Includes
- An overview of the market for companion diagnostics, including existing products on the market and detailed analysis of the competitive environments.
- Analyses of market trends, with data from 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021.
- Examination of the current state of the industry, new technologies in assay development, and potential novel commercial venues in this area of the healthcare industry.
- Identification of major commercial sectors in companion diagnostics: oncology related products vs. cardiovascular diseases and other segments.
- Profiles of major players as well as a list of current companies that have new companion diagnostics products in development.
Report Highlights
The global companion diagnostics market reached $1.1 billion in 2012. The market is expected to grow to $1.2 billion in 2013 and $3.5 billion in 2018 with a compound annual growth rate (CAGR) of 23.9%.
Report Includes
- An overview of the market for companion diagnostics, including existing products on the market and detailed analysis of the competitive environments.
- Analyses of market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
- Examination of the current state of the industry, new technologies in assay development, and potential novel commercial venues in this area of the healthcare industry.
- Identification of major commercial sectors in companion diagnostics: oncology related products vs. cardiovascular diseases and other segments.
- Comprehensive company profiles of major players, as well as a list of current companies that have new companion diagnostics products in development.
Report Highlights
-
Oncotype Dx, although not FDA-approved, is still a lead product in the breast cancer diagnosis sector. Oncotype Dx is reimbursed by most insurance companies and therefore enjoys an increase in its sales number every year. Valued at $170 million in 2010, analysts believe that by 2015, Oncotype Dx for breast cancer risk recurrence and drug regimen may reach $300 million, a compound annual growth rate (CAGR) of 12%.
-
The approval of Selzentry for first time HIV patients is creating new opportunity for the assay Trofile, a companion diagnostic to Selzentry (Celsentri outside U.S.). As a result, Trofile is expected to reach an estimated $34 million by 2015, from $24 million in 2010, a compound annual growth rate (CAGR) of 7.2%.
Related Reports
Point-of-Care Diagnostics: Technologies and Global Markets
The global market for point-of-care diagnostics was valued at $36.9 billion in 2023. It is expected to grow from $40.6 billion in 2024 to $65.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% from 2024 through 2029.
Central Nervous System (CNS) Biomarkers: Technologies and Global Markets
The global central nervous system (CNS) biomarkers market should reach $9.5 billion by 2027 from $5.7 billion in 2022 at a compound annual growth rate (CAGR) of 10.8% for the forecast period of 2022 to 2027.
Cardiac Biomarkers: Technologies and Global Markets
The global market for cardiac biomarkers is estimated to increase from $13.4 billion in 2022 to reach $23.8 billion by 2027, at a compound annual growth rate (CAGR) of 12.2% from 2022 through 2027.
Renal Biomarkers: Technologies and Global Markets
The global market for renal biomarkers is estimated to increase from $1.2 billion in 2022 to reach $1.7 billion by 2027, at a compound annual growth rate (CAGR) of 7.6% from 2022 through 2027.
Recent Reports
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Induced Pluripotent Stem Cells: Global Markets
The global market for induced pluripotent stem cells (iPSCs) is expected to grow from $3.4 billion in 2023 to reach $5.2 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.1% from 2023 to 2028.
Commercial Amino Acids
The global market for commercial amino acids was valued at $30.1 billion in 2023. It is expected to grow from $31.8 billion in 2024 to $42.8 billion by 2029, at a compound annual growth rate (CAGR) of 6.1% from 2024 through 2029.
AI in Clinical and Molecular Diagnostics Market
The global market for AI in clinical and molecular diagnostics is expected to grow from $2.6 billion in 2024 and is projected to reach $8.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.6% during the forecast period of 2024 to 2029.
Top Trending Reports
AI in Clinical and Molecular Diagnostics Market
The global market for AI in clinical and molecular diagnostics is expected to grow from $2.6 billion in 2024 and is projected to reach $8.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.6% during the forecast period of 2024 to 2029.
Point-of-Care Diagnostics: Technologies and Global Markets
The global market for point-of-care diagnostics was valued at $36.9 billion in 2023. It is expected to grow from $40.6 billion in 2024 to $65.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% from 2024 through 2029.
Medical Devices: Technologies and Global Markets
The global market for medical devices reached $739.6 billion in 2023. It is expected to grow from $810.4 billion in 2024 to $1.3 trillion by the end of 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.
CRISPR Technology: Global Markets
The global market for CRISPR technology was valued at $3.4 billion in 2023. This market is expected to grow from $3.8 billion in 2024 to $7.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2029.
Global Artificial Intelligence (AI) Market: Investments vs Potential
The global market for artificial intelligence (AI) is estimated to increase from $148.8 billion in 2023 to reach $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 39.7% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More